Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Administration of AGN-151586 and BOTOX for Glabellar Lines
NCT05496335Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2022
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised trial in glabellar lines comparing AGN-151586, BOTOX with Placebo, BOTOX (2 arms). Primary endpoint: Percentage of Participants achieving 'none' or 'mild' on the Facial Wrinkle Scale (FWS) at Day 60. Started Aug 2022; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT05496335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496335.